Marker Therapeutics, Inc. (MRKR) NASDAQ
1.42
-0.1(-6.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Marker Therapeutics, Inc.
Address
3200 Southwest Freeway
Houston, TX 77027
United States of America (the)
Phone
713 400 6400
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
July 16, 2002
Key Executives
| Name | Title | Pay | Year Born |
| Juan F. Vera | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director | 415,385 | 1980 |
| Elizabeth Donnelly | Director of Administration | 0 | N/A |
| Patricia Allison | Head of Clinical Operations | 0 | N/A |
| Robert Z. Florkiewicz | Senior Director of Molecular Biology & Virology | 0 | N/A |
| Maria-Bernadette Madel | Director of Corporate Operations & External Communications | 0 | 1990 |
| Edmund Cheung | Vice President of Human Resources | 0 | N/A |
| Mary Newman | Head of Regulatory Affairs | 0 | 1959 |
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
